ArticleAnnals of thoracic surgery short reports2025
Lobectomy vs Segmentectomy in Stage I Non-Small Cell Lung Cancer With Lymphatic Vascular Invasion.
Article in Annals of thoracic surgery short reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) constitutes 80% of new lung cancers and causes significant morbidity and mortality. Surgical interventions include lobectomy and segmentectomy. Lymphovascular invasion (LVI) correlates with reduced survival and increased recurrence; however, treatment recommendations are lacking. The aim of this study was to analyze survival and clinical characteristics of segmentectomy vs lobectomy in patients with stage I NSCLC with LVI. Methods: This retrospective cohort study, using the National Cancer Database from 2004 to 2020, identified patients with a diagnosis of NSCLC. Patients were propensity score matched by age, race, tumor size, and sex, divided into lobectomy and segmental resection groups. Statistical methods involved χ Results: Of 8028 patients meeting inclusion criteria, 7612 (94.8%) underwent lobectomy and 416 (5.2%) underwent segmentectomy. After propensity score matching, there remained no significant differences in median survival between the segmentectomy group and The lobectomy group (75.2% [95% CI, 64.1%-86.3%] vs 76.1.8% [95% CI, 66.1%-86.0%], respectively; Conclusions: The main finding of this large, retrospective cohort study is that there was no significant difference in overall disease-free survival between patients who underwent segmental resection and patients who underwent lobectomy. After 1:1 propensity matching, there remained no significant difference between the 2 groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.